0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IgG4

IgG4

Brief Information

Name:Immunoglobulin G
Target Synonym:Immunoglobulin G
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IG4-S74 Mouse Mouse Anti-Human IgG4 secondary antibody, Mouse IgG1, HRP

Synonym Name

Background

ADE has been observed in SARS, MERS and other human respiratory virus infections, which suggests a real risk of ADE for SARS-CoV-2 vaccines and antibody-based interventions. Non-neutralizing mAbs against SARS-CoV-2 should be administered to determine whether non-neutralizing antibodies enhance disease.

Clinical and Translational Updates

    Public Drug Information

    Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
    5% Human Normal Immunoglobulin (Hemarus Therapeutics) Approved Hemarus Therapeutics Immuglo HIV Infections; Leukemia, Lymphoid; Mucocutaneous Lymph Node Syndrome; Wiskott-Aldrich Syndrome; Purpura, Thrombocytopenic, Idiopathic; Agammaglobulinemia; Immunologic Deficiency Syndromes Hemarus Therapeutics 2015-08-01 HIV Infections; Wiskott-Aldrich Syndrome; Purpura, Thrombocytopenic, Idiopathic; Leukemia, Lymphoid; Agammaglobulinemia; Mucocutaneous Lymph Node Syndrome; Immunologic Deficiency Syndromes Details
    Imlifidase Mac-1 Approved Hansamed Inc Idefirix EU Rejection of renal transplantation Hansa Biopharma Ab 2020-08-25 Rejection of renal transplantation; Purpura, Thrombotic Thrombocytopenic; Rejection of organ transplantation; Renal Insufficiency, Chronic; Guillain-Barre Syndrome; Kidney Failure, Chronic Details

    Clinical Drug Information

    Name Research Code Research Phase Company Indications Clinical Trials
    Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) Phase 1 Clinical University Of California San Diego Leukemia, Myeloid, Acute Details
    Recombinant Tumor Enzyme Specific Interferon α-2b Fc Fusion (Livzon Pharmaceutical Group) A-01 Phase 1 Clinical Livzon Pharmaceutical Group Inc Solid tumours Details

    This web search service is supported by Google Inc.

    totop